|
MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Transcenta |
|
|
|
Stock and Other Ownership Interests - Transcenta |
|
|
|
Stock and Other Ownership Interests - Transcenta |
|
|
|
Stock and Other Ownership Interests - Transcenta |
|
|
|
Stock and Other Ownership Interests - Transcenta |
|
|
|
Stock and Other Ownership Interests - Transcenta |
|
|
|
Stock and Other Ownership Interests - Transcenta |
|
|
No Relationships to Disclose |
|
|
Employment - CSPC Pharmaceutical Group; MabSpace Biosciences; MabSpace, CSPC |
|
|
|
Stock and Other Ownership Interests - Transcenta |